Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07007962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07007962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Recruiting
Start date
October 24, 2025
Completion date
December 30, 2028
Enrollment
60 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia